Genentech Signs an Exclusive Option and License Agreement with Skyhawk to Discover and Develop RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases

 Genentech Signs an Exclusive Option and License Agreement with Skyhawk to Discover and Develop RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases

Genentech Signs an Exclusive Option and License Agreement with Skyhawk to Discover and Develop RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases

Shots:

  • Skyhawk to receive up front, more than $2B as option fee & milestones, royalties on sales and will utilize its SkySTAR technology platform to discover and develop RNA splicing modifiers targeting oncology & neurological disorders
  • Genentech to get an exclusive WW license to develop & commercialize RNA splicing modifiers targeting neurodegenerative diseases and cancer and will be responsible for clinical & commercial activities            
  • Skyhawk’s SkySTAR technology corrects the genetics of disease at the mRNA level in the nucleus of cells by integrating information from computational, kinetic, & structural models of RNA

Click here to read full press release/ article | Ref: PRNewswire | Image: Irish times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post